

## AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8

**AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company is participating at Redeye Theme: Alzheimer & Parkinsons on April 8, 10:55am, when CEO Martin Jönsson presents the company and its pipeline within Alzheimer's.**

Watch the livestream via <https://www.redeye.se/events/1052619/redeye-theme-alzheimer-parkinsons>

The session will also be available afterwards on AlzeCure's company page at Redeye [www.redeye.se/company/alzecure-pharma](http://www.redeye.se/company/alzecure-pharma), and on AlzeCure's website [www.alzecurepharma.se/en/presentations-and-interviews/](http://www.alzecurepharma.se/en/presentations-and-interviews/).

Time: 10.30am – 12.00pm CET, April 8

Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden

**For more information, please contact**

---

Martin Jönsson, CEO

Tel: +46 707 86 94 43

[martin.jonsson@alzecurepharma.com](mailto:martin.jonsson@alzecurepharma.com)

### About AlzeCure Pharma AB (publ)

---

AlzeCure<sup>®</sup> is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore<sup>®</sup>, Alzstatin<sup>®</sup> and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se)

## Image Attachments

---

Martin Jönsson CEO AlzeCure Pharma

## Attachments

---

AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8